CEPH Message Board - Msg: 2043583

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CEPH

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Zamin Mustafa who wrote (447)	8/25/1997 12:50:00 PM
From: Zamin Mustafa	of 998

More news CEPH up 7/8 11 1/8 Cephalon gets patents on IGF-1, cancer compound WEST CHESTER, Pa., Aug 25 (Reuter) - Cephalon Inc (CEPH) said Monday it has received European and U.S. patents for IGF-1, including recombinant human IGF-1, used in the treatment of amyotrophic lateral sclerosis (ALS) or motor-neuron disease. Cephalon said it also received a U.S. patent for IGF-1's use in treatment of any neorological disease for which non-mitotic, cholinergic neurons are at risk of dying, including head and spinal cord injury. The biopharmaceutical company said it also received U.S. patent for covering the composition CEP-2563 and the method for using the compound in pathological conditions of the prostrate. It said it also has corresponding patent applications on CEP-2563 pending worldwide. It said it is investigating CEP-2563 and certain related compounds for the potential treatment of various cancers, including prostate cancer. It said it is collaborating with TAP Holdings Inc in these efforts.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next